**Summary**
Fusion Antibodies plc, a Belfast-based contract research organization (CRO) specializing in pre-clinical antibody discovery and engineering, announced on August 5, 2025, that its U.S. patent application (No. 17/287,441) for the OptiMAL® antibody library and design method has been granted by the United States Patent and Trademark Office. This patent protects Fusions unique approach to antibody library design, which is central to its OptiMAL® platform for applications like antibody discovery, affinity maturation, and sequence optimization.
The company is also pursuing patent applications for the OptiMAL® Library in other key territories, including Europe, China, and Japan. With the U.S. patent secured, Fusion plans to present its scientific advancements at the Antibody Engineering and Therapeutics conference in San Diego in December 2025 and aims to commercially launch OptiMAL® at the same event.
Fusion’s leadership, including CSO Richard Buick and CEO Adrian Kinkaid, expressed satisfaction with the patent grant, emphasizing its importance in safeguarding the company’s intellectual property and supporting its commercial goals. The announcement coincides with the validation of OptiMAL®’s antibody binding properties, marking a significant milestone for the company’s growth strategy.
Fusion Antibodies, established in 2001 as a spin-out from Queens University Belfast, has a strong track record in antibody engineering and serves an international client base, including top global pharmaceutical companies. The company’s mission is to accelerate drug development for the healthcare industry by leveraging cutting-edge science and technology.